• In early June 2026, Recursion Pharmaceuticals presented at the Goldman Sachs 47th Annual Global Healthcare Conference and highlighted progress in its AI-enabled drug discovery platform alongside clinical updates for REC-1245 and REC-4881.
• A key insight is that initial safety signals for REC-1245 in the DHALIA solid-tumor trial and anticipated FDA feedback on REC-4881’s regulatory path are sharpening investor focus on how Recursion’s AI tools may translate into tangible clinical and regulatory outcomes.
• With REC-1245’s early safety profile and pending FDA feedback on REC-4881 now in view, we’ll examine how this news reshapes Recursion’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Recursion Pharmaceuticals Investment Narrative Recap

To own Recursion, you need to believe its AI-first approach can turn an early-stage pipeline into real drugs before cash runs thin. The latest Goldman Sachs appearance, with early safety signals from REC-1245 and looming FDA guidance on REC-4881, keeps the near-term clinical and regulatory readouts as the key catalyst, while execution risk in those small, early trials and ongoing cash burn remain the biggest concerns. The conference itself does not materially change that balance.

The most relevant update here is the initial DHALIA data for REC-1245, which showed no dose-limiting toxicities in solid tumors. That safety footing matters because it supports Recursion’s case that its AI-enabled discovery can produce viable oncology candidates, reinforcing the importance of the planned H2 2026 DHALIA readout and the upcoming FDA feedback on REC-4881 as the next meaningful tests of the story.

Yet behind the promise of AI-driven drug discovery, investors should also be aware that...

Recursion Pharmaceuticals’ narrative projects $220.9 million revenue and $35.5 million earnings by 2028.

Uncover how Recursion Pharmaceuticals' forecasts yield a $7.00 fair value, a 122% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were projecting revenue to climb toward about US$825.1 million by 2029, assuming Recursion’s AI platforms sharply accelerate pipeline progress and margins, which is far more upbeat than the baseline view and could be challenged or reinforced as REC-1245’s early safety data and REC-4881’s upcoming FDA feedback reshape how you weigh that potential against the risk of rising costs and continued losses.

Explore 6 other fair value estimates on Recursion Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Recursion Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.